Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Leukemia

Free Subscription Articles published in Eur J Haematol Retrieve available abstracts of 152 articles: HTML format

Single Articles

October 2026
1. MILOJKOVIC D, Cross NCP, Desai K, Frewin K, et al
   Adapting UK Clinical Practise in Chronic Myeloid Leukaemia in Chronic Phase to Contemporary Management Recommendations: The ADAPT 2.0 Survey.
   Eur J Haematol. 2026;117:1072-1080.
   PubMed     Abstract available
   
   
   
2. MARTINO EA, Caserta S, Vigna E, Cutrona G, et al
   To Treat or Not to Treat: Navigating Early-Stage CLL in the Era of Targeted Therapy.
   Eur J Haematol. 2026;117:750-766.
   PubMed     Abstract available
   
   
   September 2026
3. BRINK M, van der Spek AC, Doorduijn JK, de Heer K, et al
   Treatment Patterns, Outcomes and Survival Trends in T-Cell Prolymphocytic Leukemia: A Nationwide Population-Based Study in the Netherlands.
   Eur J Haematol. 2026 Sep 4. doi: 10.1111/ejh.70312.
   PubMed     Abstract available
   
   
   
4. ALBUQUERQUE TM, Sousa AVL, Rollo G, Adriano FKMS, et al
   Surgical Aspects of Patients With Leukemic Testicular Infiltration.
   Eur J Haematol. 2026;117:543-547.
   PubMed     Abstract available
   
   
   August 2026
5. ORIQUAT G, Al-Hasnaawei S, Mousa HM, Malathi H, et al
   Extracellular Vesicle-Based Approaches in Acute Myeloid Leukemia: Therapeutic Potential and Translational Challenges.
   Eur J Haematol. 2026 Aug 31. doi: 10.1111/ejh.70308.
   PubMed     Abstract available
   
   
   
6. HOFSTETTER L, Buchrits S, Sherban A, Sternbach N, et al
   Cardiac Adverse Events in Patients With Chronic Lymphocytic Leukemia Treated With First-Line Ibrutinib-Venetoclax.
   Eur J Haematol. 2026 Aug 27. doi: 10.1111/ejh.70300.
   PubMed     Abstract available
   
   
   
7. FIORENZO S, Elsa P, Alessandro S, Mario P, et al
   Long-Term Clinical Outcomes, Adherence, Persistence, and Adverse Event Management in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib.
   Eur J Haematol. 2026 Aug 14. doi: 10.1111/ejh.70292.
   PubMed     Abstract available
   
   
   
8. MOLICA S
   Navigating the Paradigm Shift in Chronic Lymphocytic Leukemia: Insights From EHA 2026.
   Eur J Haematol. 2026 Aug 5. doi: 10.1111/ejh.70288.
   PubMed    
   
   
   
9. KENNEDY VE, Peretz CAC, Koh A, Tran E, et al
   Multiomic Single-Cell Sequencing Identifies BCR::ABL1 as an Acquired Resistance Mechanism in FLT3+ AML.
   Eur J Haematol. 2026;117:501-503.
   PubMed     Abstract available
   
   
   
10. MARTINO EA, Chiarenza A, Mancuso S, Rossi M, et al
    Regional Standardization of CLL Management: Results of a Delphi Consensus Process.
    Eur J Haematol. 2026;117:442-447.
    PubMed     Abstract available
    
    
    
11. MARTINO EA, Caserta S, Vigna E, Bruzzese A, et al
    From Time-Limited Therapy to Treatment-Free Observation: The Evolving Role of MRD in CLL Management.
    Eur J Haematol. 2026;117:305-319.
    PubMed     Abstract available
    
    
    
12. KUTSCH N, Ligtvoet R, Robrecht S, Linde H, et al
    Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry.
    Eur J Haematol. 2026;117:351-357.
    PubMed     Abstract available
    
    
    
13. MOLICA S, Lucignano M, Villa MR, Mettivier L, et al
    Bridging Trials and Real Life in Fixed-Duration BTKi-Venetoclax for CLL: A Delphi-Enhanced Synthesis Incorporating Artificial Intelligence (AI) Benchmarks.
    Eur J Haematol. 2026;117:366-374.
    PubMed     Abstract available
    
    
    July 2026
14. TAKAOKA K, Mott S, Yodsuwan R, Saowapa S, et al
    KRAS Mutations Predict Inferior Post-Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations.
    Eur J Haematol. 2026 Jul 24. doi: 10.1111/ejh.70270.
    PubMed     Abstract available
    
    
    
15. RUSSO S, Capodanno I, Tiribelli M, Miggiano MC, et al
    Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real-Life Survey Within the Italian Chronic Myeloid Leukemia Network.
    Eur J Haematol. 2026 Jul 22. doi: 10.1111/ejh.70268.
    PubMed     Abstract available
    
    
    
16. KJAER CW, Sorum ME, De Pietri S, Moser C, et al
    Pronounced Reductions in Plasma Citrulline Indicate Severe Intestinal Mucosal Barrier Injury During Induction Therapy for Pediatric Acute Myeloid Leukemia.
    Eur J Haematol. 2026 Jul 17. doi: 10.1111/ejh.70267.
    PubMed     Abstract available
    
    
    
17. WANG Y, Xiao R, Huang X, Xiao Y, et al
    Feasibility and Safety of Venetoclax for Cytoreduction During Induction Therapy in Newly Diagnosed Acute Promyelocytic Leukemia.
    Eur J Haematol. 2026 Jul 13. doi: 10.1111/ejh.70264.
    PubMed     Abstract available
    
    
    
18. MOLICA S
    Polypharmacy in Chronic Lymphocytic Leukemia in the Era of Targeted Agents: A Medication Stewardship Perspective.
    Eur J Haematol. 2026 Jul 12. doi: 10.1111/ejh.70265.
    PubMed     Abstract available
    
    
    June 2026
19. MAY M, Limon De la Rosa N, Duarte C, Boosma G, et al
    Analysis of CD8 Cytotoxic T-Cells in Patients With Myelodysplastic Neoplasms and T-Cell Large Granulocyte Lymphocytic Leukemia.
    Eur J Haematol. 2026 Jun 29. doi: 10.1111/ejh.70251.
    PubMed    
    
    
    
20. CHAOUI D, Stocker N
    Beyond Frailty Scores: Unmet Needs and Tailored Treatment Strategies in Patients With Chronic Lymphocytic Leukemia Aged >/= 80 Years.
    Eur J Haematol. 2026 Jun 22. doi: 10.1111/ejh.70248.
    PubMed     Abstract available
    
    
    
21. SKUDAR S
    Dynamic Frailty Assessment in Older Adults With Acute Myeloid Leukemia: From Treatment Eligibility to Treatment Adaptation.
    Eur J Haematol. 2026 Jun 15. doi: 10.1111/ejh.70243.
    PubMed    
    
    
    
22. BISCHOF L, Egger-Heidrich K, Schneider M, Friedrich G, et al
    Digital Surveillance After Allogeneic Hematopoietic Stem Cell Transplantation Guides Therapeutic Interventions to Reduce Non-Relapse Mortality.
    Eur J Haematol. 2026;116:937-942.
    PubMed     Abstract available
    
    
    
23. EHLERS LH, Levin MD, van der Klift M, Jensen MB, et al
    Cost-Effectiveness of Venetoclax-Based Treatment in Treatment-Naive Fit Patients With CLL Without TP53 Aberrations.
    Eur J Haematol. 2026;116:873-882.
    PubMed     Abstract available
    
    
    
24. BATYRBEKOVA N, Landtblom AR, Hultcrantz M, Szulkin R, et al
    Risk of Transformation to Acute Myeloid Leukaemia and Myelodysplastic Syndromes in Patients With Myeloproliferative Neoplasms Over Attained Age and Time Since Diagnosis: A Nationwide Cohort Study.
    Eur J Haematol. 2026;116:850-862.
    PubMed     Abstract available
    
    
    May 2026
25. BRUZZESE A, Martino EA, Caserta S, Alvaro ME, et al
    Frailty and Fitness in Older Adults With Acute Myeloid Leukemia: From Chronological Age to Multiparametric Assessment.
    Eur J Haematol. 2026 May 25. doi: 10.1111/ejh.70223.
    PubMed     Abstract available
    
    
    
26. SALAH AN, Mansour RM, El-Sayyad GS, Moustafa HAM, et al
    Epigenetics and In Silico Transcriptome Analysis of Pediatric Acute Myeloid Leukemia.
    Eur J Haematol. 2026 May 22. doi: 10.1111/ejh.70230.
    PubMed     Abstract available
    
    
    
27. OU W, Yu Y, Zhu X, Jiang J, et al
    Combined Early Steroid Response and MRD Improve Risk Stratification in Pediatric Acute Lymphoblastic Leukemia: The CCCG-ALL-2015 Study.
    Eur J Haematol. 2026 May 18. doi: 10.1111/ejh.70222.
    PubMed     Abstract available
    
    
    
28. UCHIDA Y, Tateo S, Wakao M, Shinchi H, et al
    Development of Chimeric Antigen Receptor-Modified NK Cells for the Immunotherapy of Adult T-Cell Leukemia/Lymphoma.
    Eur J Haematol. 2026 May 3. doi: 10.1111/ejh.70199.
    PubMed     Abstract available
    
    
    
29. ISHIKAWA C, Mori N
    Role of Nek2 and Hec1 in HTLV-1-Infected T-Cell Lines.
    Eur J Haematol. 2026;116:635-645.
    PubMed     Abstract available
    
    
    
30. WU N, Kong J, Lv M, Mo XD, et al
    Bridging With Chimeric Antigen Receptor T-Cell Therapy or Chemotherapy to Allo-HSCT in B-ALL: A Comparison of Treatment Complications and Survival.
    Eur J Haematol. 2026;116:615-624.
    PubMed     Abstract available
    
    
    April 2026
31. SONG L, Wei X, Zhai Z, Wang A, et al
    Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.
    Eur J Haematol. 2026 Apr 21. doi: 10.1111/ejh.70164.
    PubMed     Abstract available
    
    
    
32. CASERTA S, Martino EA, Lofaro D, Vigna E, et al
    First-Line Treatment of IGHV-Unmutated Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Targeted and Chemoimmunotherapy Regimens.
    Eur J Haematol. 2026 Apr 14. doi: 10.1111/ejh.70191.
    PubMed     Abstract available
    
    
    
33. BRUZZESE A, Vigna E, Martino EA, Caserta S, et al
    Targeting the Menin-KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation.
    Eur J Haematol. 2026 Apr 2. doi: 10.1111/ejh.70186.
    PubMed     Abstract available
    
    
    March 2026
34. GOULARTE MN, Miyamoto MH, de Lacerda MP
    Venetoclax Combined With Intensive Chemotherapy Regimens for Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Systematic Review and Single-Arm Meta-Analysis.
    Eur J Haematol. 2026 Mar 25. doi: 10.1111/ejh.70175.
    PubMed     Abstract available
    
    
    
35. BRUZZESE A, Vigna E, Martino EA, Caserta S, et al
    Ph-Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs.
    Eur J Haematol. 2026 Mar 15. doi: 10.1111/ejh.70169.
    PubMed     Abstract available
    
    
    
36. MOLICA S, Allsup D
    Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.
    Eur J Haematol. 2026 Mar 12. doi: 10.1111/ejh.70160.
    PubMed     Abstract available
    
    
    
37. MESSORI A
    Updating Efficacy of First-Line Treatments for Chronic Lymphocytic Leukemia: Indirect Comparisons Based on Recent Data Favor the Combination of Acalabrutinib Plus Obinutuzumab.
    Eur J Haematol. 2026 Mar 2. doi: 10.1111/ejh.70150.
    PubMed    
    
    
    February 2026
38. GAIDANO G, Danesi R
    Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives.
    Eur J Haematol. 2026 Feb 24. doi: 10.1111/ejh.70144.
    PubMed     Abstract available
    
    
    
39. TIDSWELL R, Owen C, Shafey M, Perry S, et al
    Real-World Selection of Venetoclax-Obinutuzumab Versus BTK Inhibitor Therapy for Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Eur J Haematol. 2026 Feb 16. doi: 10.1111/ejh.70137.
    PubMed     Abstract available
    
    
    January 2026
40. SABBAGH C
    Distribution of ABO/Rh Blood Types Across Childhood Leukemia Subtypes: A Retrospective Cohort Study of 540 Pediatric Patients.
    Eur J Haematol. 2026 Jan 30. doi: 10.1111/ejh.70127.
    PubMed     Abstract available
    
    
    
41. MAHESWARAN S, Gordon CD, Chen EC, Patel SA, et al
    Challenges and Solutions to Implementation of Chimeric Antigen Receptor Therapies in Acute Myeloid Leukemia.
    Eur J Haematol. 2026 Jan 23. doi: 10.1111/ejh.70120.
    PubMed     Abstract available
    
    
    
42. SEKAR AJ, Sakthivel S, Valsala Gopalakrishnan A, Vashishth R, et al
    An Overview of Chronic Myeloid Leukemia Treatment: From Tyrosine Kinase Inhibitors to Novel and Emerging Therapies.
    Eur J Haematol. 2026 Jan 13. doi: 10.1111/ejh.70110.
    PubMed     Abstract available
    
    
    December 2025
43. NOURBAKHSH SMK, Valadkhani C, Safaei H
    Clinical and Laboratory Indicators of Pediatric Leukemia and Neuroblastoma in Musculoskeletal Presentations: A Retrospective Study From a Resource-Limited Setting.
    Eur J Haematol. 2025 Dec 29. doi: 10.1111/ejh.70106.
    PubMed     Abstract available
    
    
    
44. HO TN, Willard P, Murray GF, Liu L, et al
    Improvements in Real-World Survival in the Setting of a Recent Paradigm Shift in Acute Myeloid Leukemia Treatment.
    Eur J Haematol. 2025 Dec 23. doi: 10.1111/ejh.70087.
    PubMed     Abstract available
    
    
    
45. KASMI D, Bisegna ML, Carmosino I, Scalzulli E, et al
    Outpatient Versus Inpatient Azacitidine Plus Venetoclax Regimen in Elderly Acute Myeloid Leukemia: A Multicenter Retrospective Analysis.
    Eur J Haematol. 2025 Dec 21. doi: 10.1111/ejh.70102.
    PubMed     Abstract available
    
    
    
46. SAKTHIVEL M, Katneni P, Nataraja RM, Pacilli M, et al
    Central Venous Access Device Complications in Children With Leukemia: A Systematic Review and Meta-Analysis.
    Eur J Haematol. 2025 Dec 15. doi: 10.1111/ejh.70080.
    PubMed     Abstract available
    
    
    
47. CUNNINGHAM I, Fisher RA, Yang J, Guo Y, et al
    Dasatinib Produces Lengthy Remissions of Extramedullary Leukemia: A Retrospective Observational Study.
    Eur J Haematol. 2025 Dec 10. doi: 10.1111/ejh.70051.
    PubMed     Abstract available
    
    
    
48. TVEDT THA, Qvigstad C, Nezvalova-Henriksen K, Bergland BS, et al
    Three-Month Posttransplant Lipidomic Profile Reflects Acute GVHD but Not Chronic GVHD Risk in Allogeneic Stem Cell Recipients.
    Eur J Haematol. 2025;115:565-573.
    PubMed     Abstract available
    
    
    November 2025
49. MARTINO EA, Caserta S, Vigna E, Bruzzese A, et al
    Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies.
    Eur J Haematol. 2025 Nov 25. doi: 10.1111/ejh.70065.
    PubMed     Abstract available
    
    
    
50. VIGNA E, Bruzzese A, Mule A, Sucato G, et al
    Real-World Evaluation of Oral Decitabine/Cedazuridine in Elderly Patients With Acute Myeloid Leukemia.
    Eur J Haematol. 2025 Nov 6. doi: 10.1111/ejh.70057.
    PubMed    
    
    
    October 2025
51. RONGJIE L, Lijuan Q, Bailing Z, Liyue K, et al
    Spontaneous Remission and Subsequent Relapse in Pediatric Acute Myeloid Leukemia (AML-M5): A Case Report and Literature Review.
    Eur J Haematol. 2025 Oct 29. doi: 10.1111/ejh.70044.
    PubMed     Abstract available
    
    
    
52. VIGNA E, Bruzzese A, Martino EA, Corsonello A, et al
    Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents.
    Eur J Haematol. 2025 Oct 29. doi: 10.1111/ejh.70058.
    PubMed     Abstract available
    
    
    
53. OLIVA S, Molica S
    Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy.
    Eur J Haematol. 2025 Oct 21. doi: 10.1111/ejh.70047.
    PubMed     Abstract available
    
    
    
54. LIEW-LITTORIN M, Deleskog-Spangberg L, Deneberg S, Janosi J, et al
    Second- and Third-Line Salvage Chemotherapy Followed by Allogeneic Stem Cell Transplantation Leads to High Survival Rates in Primary Refractory AML-A Population-Based Study.
    Eur J Haematol. 2025;115:423-432.
    PubMed     Abstract available
    
    
    September 2025
55. SRINIVASAN T, Mallik N, Sachdeva MUS, Bose P, et al
    CD48 Is a Robust Marker and a Useful Addition for Assessment of Measurable Residual Disease in T-Cell Acute Lymphoblastic Leukemia.
    Eur J Haematol. 2025 Sep 13. doi: 10.1111/ejh.70035.
    PubMed     Abstract available
    
    
    
56. TOKUDA C, Iwasaki M, Kanda J, Kondo T, et al
    Significance of Pre- and Posttransplant Minimal Residual Disease on Transplant Outcomes in Core-Binding Factor Acute Myeloid Leukemia.
    Eur J Haematol. 2025 Sep 9. doi: 10.1111/ejh.70024.
    PubMed     Abstract available
    
    
    
57. HANSEN MH, Gulmir R, Cedile O, Dahlmann SK, et al
    Performance of Rapid Clonotyping of Chronic Lymphocytic Leukemia Using Flongle Flow-Cell Nanopore Sequencing of IGH Rearrangements.
    Eur J Haematol. 2025 Sep 8. doi: 10.1111/ejh.70030.
    PubMed     Abstract available
    
    
    August 2025
58. PALUMBO FE, Vetro C, Calafiore V, Duminuco A, et al
    Extramedullary Acute Myeloid Leukemia: Evaluating Azacitidine-Venetoclax Combination Outcomes and the Role of Molecular Genetics and Bone Marrow Involvement.
    Eur J Haematol. 2025 Aug 14. doi: 10.1111/ejh.70021.
    PubMed    
    
    
    
59. STEIDEL E, Orhan E, Rasche M, Pigazzi M, et al
    Prognostic Value of Molecular Genetic Measurable Residual Disease (MRD) Monitoring in Pediatric Acute Myeloid Leukemia Expressing KMT2A::MLLT10.
    Eur J Haematol. 2025 Aug 13. doi: 10.1111/ejh.70019.
    PubMed     Abstract available
    
    
    
60. FENWARTH L, Podvin B, Vasseur L, Lebon D, et al
    Myeloid Neoplasms With Erythroid Predominance and Excess Blasts in Young Adults Exhibit Distinct Genetic Profiles.
    Eur J Haematol. 2025;115:185-192.
    PubMed     Abstract available
    
    
    
61. BAHRAMI HEZAVEH E, Yan J, Zhao D, Wangulu C, et al
    Genetic Landscape and Risk Stratification of AML With Hyperdiploid Karyotype.
    Eur J Haematol. 2025;115:165-175.
    PubMed     Abstract available
    
    
    July 2025
62. MAHAMEED B, Sharf G, Tadmor T, Kleinstern G, et al
    Gender Disparities in Health-Related Quality of Life in Patients With Chronic Lymphocytic Leukemia: Impact of Treatment Modality.
    Eur J Haematol. 2025 Jul 31. doi: 10.1111/ejh.70017.
    PubMed     Abstract available
    
    
    June 2025
63. LAGANA A, Scalzulli E, Carmosino I, Bisegna ML, et al
    Treatment Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML): Analysis of Predictive Factors and Novel Baseline Scoring System to Predict Molecular Relapse.
    Eur J Haematol. 2025 Jun 30. doi: 10.1111/ejh.70006.
    PubMed     Abstract available
    
    
    
64. BRUZZESE A, Vigna E, Martino EA, Amodio N, et al
    Treatment-Free Remission in Chronic Myeloid Leukemia: Revisiting the "W" Questions.
    Eur J Haematol. 2025 Jun 23. doi: 10.1111/ejh.70000.
    PubMed     Abstract available
    
    
    
65. LI Y, Liu X, Li W, Hou L, et al
    Diagnostic and Prognostic Significance of Peripheral Blood RASSF1A, P16, and PTGER4 Gene Methylation in Adult Acute Leukemia.
    Eur J Haematol. 2025 Jun 3. doi: 10.1111/ejh.14442.
    PubMed     Abstract available
    
    
    
66. KRUSZEWSKI M, Schmoor C, Berg T, Rehman UU, et al
    Sensitization of Non-M3 Acute Myeloid Leukemia Blasts to All-Trans Retinoic Acid by the LSD1 Inhibitor Tranylcypromine: TRANSATRA Phase I Study.
    Eur J Haematol. 2025 Jun 3. doi: 10.1111/ejh.14426.
    PubMed     Abstract available
    
    
    
67. TADMOR T, Melamed G, Alapi H, Rokach L, et al
    CLLAF SCORE-A New Risk Score for Predicting Atrial Fibrillation in Treatment-Naive CLL Patients Initiating First- and Second-Generation BTK Inhibitor Therapy.
    Eur J Haematol. 2025;114:1011-1019.
    PubMed     Abstract available
    
    
    May 2025
68. ALNUGHMUSH A, Alyamany R, Remberger M, Pasic I, et al
    Impact of Conditioning Intensity on Survival in Adult Patients (< 65 Years) With Acute Myeloid Leukemia Receiving Antithymocyte Globulin and Post-Transplantation Cyclophosphamide Based GVHD Prophylaxis.
    Eur J Haematol. 2025 May 28. doi: 10.1111/ejh.14438.
    PubMed     Abstract available
    
    
    
69. KOCKEROLS C, Valk PJM, Hogenbirk P, Geelen I, et al
    Treatment-Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML Patients.
    Eur J Haematol. 2025;114:900-907.
    PubMed     Abstract available
    
    
    April 2025
70. FRISCH A, Ganzel C, Ofran Y, Krayem B, et al
    Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission.
    Eur J Haematol. 2025;114:641-649.
    PubMed     Abstract available
    
    
    March 2025
71. LOHRBERG M, Heber M, Ries L, Markus K, et al
    Dual Targeting of Pim and PI3 Kinases in Mature T-Cell Lymphoma.
    Eur J Haematol. 2025 Mar 31. doi: 10.1111/ejh.14420.
    PubMed     Abstract available
    
    
    
72. CHEN D, Cantu M, Siddon A, Weinberg OK, et al
    TP53-Mutated Acute Myeloid Leukemia and Blast Phase Myeloproliferative Neoplasm: Distinct Mutation Leads to Poorer Prognosis.
    Eur J Haematol. 2025 Mar 28. doi: 10.1111/ejh.14421.
    PubMed     Abstract available
    
    
    
73. POONSOMBUDLERT K, Yodsuwan R, Mott S, Crawford K, et al
    Effect of NPM1 Mutation Subtype and Co-Mutation Patterns on the Outcomes of Acute Myeloid Leukemia.
    Eur J Haematol. 2025 Mar 19. doi: 10.1111/ejh.14415.
    PubMed     Abstract available
    
    
    
74. ZHENG R, Gagan JR, Botten GA, Koduru P, et al
    Genomic Landscape of Mixed Phenotype Acute Leukemia Associated With Immunophenotypic Lineage Predominance: Impact on Diagnosis and Treatment.
    Eur J Haematol. 2025 Mar 18. doi: 10.1111/ejh.14414.
    PubMed     Abstract available
    
    
    
75. CHUNG C, Doan D
    Targeting the Immune Microenvironment in Chronic Lymphocytic Leukemia: An Evolving Therapeutic Strategy.
    Eur J Haematol. 2025 Mar 11. doi: 10.1111/ejh.14408.
    PubMed     Abstract available
    
    
    
76. NAGAFUJI K, Ito Y, Miyamoto T, Eto T, et al
    Clinical Impact of Continuous Dasatinib Administration on the Prognosis of Patients With BCR::ABL1 Acute Lymphoblastic Leukemia: Result of the Prospective MRD2014 Study Conducted by Fukuoka Blood and Marrow Transplantation Group (FBMTG).
    Eur J Haematol. 2025 Mar 7. doi: 10.1111/ejh.14407.
    PubMed     Abstract available
    
    
    
77. BRUZZESE A, Martino EA, Labanca C, Carida G, et al
    Therapeutic Strategies for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies.
    Eur J Haematol. 2025 Mar 6. doi: 10.1111/ejh.14405.
    PubMed     Abstract available
    
    
    
78. GHIMIRE B, Zimmer M, Donthireddy V
    TP53-Mutated Acute Myeloid Leukemia: Review of Treatment and Challenges.
    Eur J Haematol. 2025 Mar 4. doi: 10.1111/ejh.14404.
    PubMed     Abstract available
    
    
    February 2025
79. VEYHE SR, Hansen MH, Cedile O, Moller MB, et al
    A Case-Driven Multi-Omics Analysis for Longitudinal Ibrutinib Response Evaluation of Patients With Chronic Lymphocytic Leukemia.
    Eur J Haematol. 2025 Feb 23. doi: 10.1111/ejh.14397.
    PubMed     Abstract available
    
    
    
80. CASTELLET H, Ramil G, Carricondo M, Onate G, et al
    Measurable Residual Disease in UBTF-TD Adult Acute Myeloid Leukemia.
    Eur J Haematol. 2025 Feb 23. doi: 10.1111/ejh.14402.
    PubMed    
    
    
    
81. ROBAK T, Robak M, Majchrzak A, Krawczynska A, et al
    Atypical Hairy Cell Leukemia-The Current Status and Future Directions.
    Eur J Haematol. 2025 Feb 10. doi: 10.1111/ejh.14388.
    PubMed     Abstract available
    
    
    
82. BENOIT TM, Bachofner A, Wolfensberger N, Zaugg-Berger Y, et al
    Inferior Overall Survival After Haploidentical Donor Lymphocyte Infusions in Relapsed Myeloid Neoplasms.
    Eur J Haematol. 2025;114:315-324.
    PubMed     Abstract available
    
    
    
83. BRESSER H, Schmoor C, Grishina O, Pfeifer D, et al
    Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.
    Eur J Haematol. 2025;114:231-237.
    PubMed     Abstract available
    
    
    January 2025
84. HYPPOLITO JE, Arcuri LJ, Vicente A, Farnese V, et al
    Central Nervous System Involvement in Chronic Lymphocytic Leukemia: A Case-Series.
    Eur J Haematol. 2025 Jan 31. doi: 10.1111/ejh.14389.
    PubMed    
    
    
    
85. YANG MM, Singh R, Haugen M, Duff A, et al
    Adherence to 6-Mercaptopurine (6-MP) and Habit Strength in Pediatric Acute Lymphoblastic Leukemia (ALL).
    Eur J Haematol. 2025 Jan 20. doi: 10.1111/ejh.14386.
    PubMed     Abstract available
    
    
    
86. ZALAPA-SOTO J, Rios-Olais FA, Chacon-Rangel LC, Mora-Canas A, et al
    Hyper-CVAD and Modified CALGB-10403 Regimens in Adult Patients With Philadelphia-Negative Acute Lymphoblastic Leukemia: A Comparative Study.
    Eur J Haematol. 2025 Jan 7. doi: 10.1111/ejh.14381.
    PubMed     Abstract available
    
    
    
87. BRUZZESE A, Martino EA, Labanca C, Mendicino F, et al
    Advances and Challenges in Quizartinib-Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies.
    Eur J Haematol. 2025 Jan 6. doi: 10.1111/ejh.14383.
    PubMed     Abstract available
    
    
    
88. BERTON G, Hospital MA, Garciaz S, Rouzaud C, et al
    Outcomes of Elderly Patients Admitted to the Intensive Care Unit for Newly Diagnosed Acute Myeloid Leukemia.
    Eur J Haematol. 2025 Jan 6. doi: 10.1111/ejh.14366.
    PubMed     Abstract available
    
    
    
89. JENSEN ABH, Andersen HRP, Jensen ST, Jensen CF, et al
    Musculoskeletal Symptoms and Misdiagnoses in Children With Acute Myeloid Leukaemia: A Nationwide Cohort Study.
    Eur J Haematol. 2025;114:57-69.
    PubMed     Abstract available
    
    
    December 2024
90. PUCKRIN R, Owen C, Peters A
    Underrepresentation of Small Lymphocytic Lymphoma in Clinical Trials for Chronic Lymphocytic Leukemia.
    Eur J Haematol. 2024 Dec 27. doi: 10.1111/ejh.14376.
    PubMed     Abstract available
    
    
    
91. TANG MW, Van der Tuin D, Aydin M, Heijmans J, et al
    Comparison of HiDAC Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome.
    Eur J Haematol. 2024 Dec 26. doi: 10.1111/ejh.14370.
    PubMed     Abstract available
    
    
    
92. ROWE M, Babushok D, Carroll M, Carulli A, et al
    Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen.
    Eur J Haematol. 2024 Dec 26. doi: 10.1111/ejh.14371.
    PubMed     Abstract available
    
    
    November 2024
93. MORT JF, Brighton D, DiBenedetto S, Wells L, et al
    Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia.
    Eur J Haematol. 2024 Nov 27. doi: 10.1111/ejh.14354.
    PubMed     Abstract available
    
    
    
94. YALNIZ FF, Johnson A, Alnimer Y, Chahine Z, et al
    Unveiling the Genetic and Clinical Differences of Acute Myeloid Leukemia (AML) in Obese Patients.
    Eur J Haematol. 2024 Nov 13. doi: 10.1111/ejh.14338.
    PubMed     Abstract available
    
    
    
95. CHEN EY, Dahlen T, Stenke L, Bjorkholm M, et al
    Loss in Overall and Quality-Adjusted Life Expectancy for Patients With Chronic-Phase Chronic Myeloid Leukemia.
    Eur J Haematol. 2024 Nov 6. doi: 10.1111/ejh.14328.
    PubMed     Abstract available
    
    
    
96. SMITH E, Atenafu EG, Bankar A, Chan S, et al
    Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1-mutated AML.
    Eur J Haematol. 2024;113:716-726.
    PubMed     Abstract available
    
    
    October 2024
97. SHACHAM-ABULAFIA A, Volcheck Y, Ellis M, Shapira S, et al
    Asciminib in Advanced-Line Treatment of Chronic Myeloid Leukemia.
    Eur J Haematol. 2024 Oct 21. doi: 10.1111/ejh.14330.
    PubMed     Abstract available
    
    
    
98. BRUZZESE A, Martino EA, Labanca C, Mendicino F, et al
    Therapy-Related Acute Promyelocytic Leukemia: Case Series and Current Insights.
    Eur J Haematol. 2024 Oct 13. doi: 10.1111/ejh.14327.
    PubMed     Abstract available
    
    
    September 2024
99. MURRAY GF, Bouligny IM, Ho T, Gor J, et al
    Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia.
    Eur J Haematol. 2024 Sep 24. doi: 10.1111/ejh.14308.
    PubMed     Abstract available
    
    
    
100. STEINER N, Massoud R, Richter J, Perekhrestenko T, et al
     Comparable Results Between 8 and 12 Gray TBI in Combination With Fludarabine and Post-Transplant Cyclophosphamide in MRD-Negative but Not in MRD-Positive Acute Lymphoblastic Leukemia Patients Transplanted in First Complete Remission.
     Eur J Haematol. 2024 Sep 19. doi: 10.1111/ejh.14305.
     PubMed     Abstract available
     
     
     
101. BUCELLI C, Capodanno I, Miggiano MC, Cavazzini F, et al
     Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study.
     Eur J Haematol. 2024 Sep 12. doi: 10.1111/ejh.14299.
     PubMed     Abstract available
     
     
     
102. WILLE K, Dumke M, Wilsdorf N, Sadjadian P, et al
     Venetoclax Combined With FLAG-IDA in Refractory or Relapsed Acute Myeloid Leukemia.
     Eur J Haematol. 2024 Sep 9. doi: 10.1111/ejh.14302.
     PubMed     Abstract available
     
     
     
103. ISHIKAWA C, Mori N
     A New Strategy for Adult T-Cell Leukemia Treatment Targeting Glycogen Synthase Kinase-3beta.
     Eur J Haematol. 2024 Sep 6. doi: 10.1111/ejh.14300.
     PubMed     Abstract available
     
     
     
104. LIN S, Liao N, Li X, Yang L, et al
     Prognosis of pediatric BCP-ALL with IKZF1 deletions and impact of intensive chemotherapy: Results of SCCLG-2016 study.
     Eur J Haematol. 2024;113:357-370.
     PubMed     Abstract available
     
     
     August 2024
105. SOUA A, Gilhodes J, Iat A, Hicheri Y, et al
     Venetoclax-based non-intensive induction followed by allogenic stem-cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics.
     Eur J Haematol. 2024 Aug 11. doi: 10.1111/ejh.14290.
     PubMed     Abstract available
     
     
     July 2024
106. RANTI J, Pudas H, Ranta M, Tuominen S, et al
     Treatment and clinical outcomes of patients with acute myeloid leukemia in Finland 2010-2020: A retrospective analysis of electronic health records.
     Eur J Haematol. 2024 Jul 29. doi: 10.1111/ejh.14272.
     PubMed     Abstract available
     
     
     
107. ACKER F, Chromik J, Tiedjen E, Wolf S, et al
     Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy.
     Eur J Haematol. 2024 Jul 18. doi: 10.1111/ejh.14278.
     PubMed     Abstract available
     
     
     
108. KOCKEROLS C, Valk PJM, Janssen JJWM, Hogenbirk P, et al
     Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients.
     Eur J Haematol. 2024 Jul 12. doi: 10.1111/ejh.14271.
     PubMed     Abstract available
     
     
     
109. LINES M, Kemper RM, Wallace J, Alexander T, et al
     Use of allopurinol to manage skewed 6-mercaptopurine metabolism in pediatric maintenance acute lymphoblastic leukemia treatment.
     Eur J Haematol. 2024 Jul 11. doi: 10.1111/ejh.14273.
     PubMed     Abstract available
     
     
     
110. GUEUNING C, Lazaro E, Dupuy H, Leonard C, et al
     Characteristics of large granular lymphocyte leukemia associated with variable common immunodeficiency disorders: A study of 12 cases.
     Eur J Haematol. 2024 Jul 10. doi: 10.1111/ejh.14265.
     PubMed     Abstract available
     
     
     June 2024
111. SKIPPER MT, Birkebaek N, Jensen RB, Rank CU, et al
     Pancreas-related persisting sequelae in ALL survivors with a history of asparaginase-associated pancreatitis: A part of the ALL-STAR study.
     Eur J Haematol. 2024;112:944-956.
     PubMed     Abstract available
     
     
     
112. GERHARDT A, Dorfel S, Schulz H, Schlag R, et al
     Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study.
     Eur J Haematol. 2024;112:927-937.
     PubMed     Abstract available
     
     
     
113. KUTSCH N, Godel P, Voltin CA, Hallek M, et al
     Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation.
     Eur J Haematol. 2024;112:984-987.
     PubMed     Abstract available
     
     
     May 2024
114. TAGHILOO S, Asgarian-Omran H
     Cross-talk between leukemic and immune cells at the tumor microenvironment in chronic lymphocytic leukemia: An update review.
     Eur J Haematol. 2024 May 2. doi: 10.1111/ejh.14224.
     PubMed     Abstract available
     
     
     
115. KUTSCH N, Giza A, Robrecht S, Stumpf J, et al
     Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
     Eur J Haematol. 2024 May 1. doi: 10.1111/ejh.14220.
     PubMed     Abstract available
     
     
     April 2024
116. AFTANDILIAN C, Bito XR, Berman D, Zhang A, et al
     Plasma microbial cell-free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia.
     Eur J Haematol. 2024 Apr 24. doi: 10.1111/ejh.14216.
     PubMed     Abstract available
     
     
     
117. MARRA JD, Galli E, Giammarco S, Metafuni E, et al
     CAR-T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation.
     Eur J Haematol. 2024 Apr 21. doi: 10.1111/ejh.14217.
     PubMed     Abstract available
     
     
     
118. MIKLOS E, Oliver TP, Adam K, Eva K, et al
     Fix low dose venetoclax-azacitidine treatment of unfit acute myeloid leukemia patients.
     Eur J Haematol. 2024 Apr 21. doi: 10.1111/ejh.14213.
     PubMed     Abstract available
     
     
     
119. GRONLUND JK, Veigaard C, Juhl-Christensen C, Skou AS, et al
     Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning.
     Eur J Haematol. 2024;112:601-610.
     PubMed     Abstract available
     
     
     
120. DELANOTE V, Callens R, Vogelaers D, Deeren D, et al
     Screening for multidrug-resistant organisms in high-risk hospitalized patients with hematologic diseases.
     Eur J Haematol. 2024;112:627-632.
     PubMed     Abstract available
     
     
     
121. PETIT C, Saillard C, Mohty B, Hicheri Y, et al
     Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.
     Eur J Haematol. 2024;112:530-537.
     PubMed     Abstract available
     
     
     
122. ISHIKAWA C, Mori N
     Pivotal role of dihydroorotate dehydrogenase as a therapeutic target in adult T-cell leukemia.
     Eur J Haematol. 2024 Apr 1. doi: 10.1111/ejh.14209.
     PubMed     Abstract available
     
     
     March 2024
123. POONSOMBUDLERT K, Mott S, Miller B, Dhakal P, et al
     Transplant versus no transplant in myelodysplastic syndrome and acute myeloid leukemia with TP53 mutation; a referral center experience.
     Eur J Haematol. 2024 Mar 21. doi: 10.1111/ejh.14199.
     PubMed     Abstract available
     
     
     
124. ZHANG X, Zhang K, Zhang J, Chang W, et al
     DNMTs-mediated SOCS3 methylation promotes the occurrence and development of AML.
     Eur J Haematol. 2024;112:439-449.
     PubMed     Abstract available
     
     
     
125. GARCIA-POUTON N, Ortiz-Maldonado V, Peyrony O, Chumbita M, et al
     Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy.
     Eur J Haematol. 2024;112:371-378.
     PubMed     Abstract available
     
     
     February 2024
126. GAO J, Santana-Santos L, Fu L, Alvey E, et al
     Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11.
     Eur J Haematol. 2024 Feb 22. doi: 10.1111/ejh.14192.
     PubMed     Abstract available
     
     
     
127. SUN Y, Zhu G, Zhong H
     Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC-MRD and treatment guidance for elderly patients.
     Eur J Haematol. 2024 Feb 11. doi: 10.1111/ejh.14187.
     PubMed     Abstract available
     
     
     
128. MELLINGHOFF SC, Robrecht S, Sprute R, Mayer L, et al
     Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.
     Eur J Haematol. 2024 Feb 4. doi: 10.1111/ejh.14170.
     PubMed     Abstract available
     
     
     
129. INFANTE JB, Esteves GV, Raposo J, de Lacerda JF, et al
     Disseminated intravascular coagulation score evolution in 48 h predicts early death in acute promyelocytic leukemia patients.
     Eur J Haematol. 2024 Feb 2. doi: 10.1111/ejh.14177.
     PubMed     Abstract available
     
     
     
130. SEVOYAN A, Mekinian A, Chermat F, Ades L, et al
     MDS/CMML from resource-limited region: Characteristics and comparison to tertiary reference European center.
     Eur J Haematol. 2024;112:296-300.
     PubMed     Abstract available
     
     
     January 2024
131. WIESEN MHJ, Stemler J, Fietz C, Joisten C, et al
     Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography-tandem mass spectrometry: Application to a cohort of patients with acute myeloid leukemia.
     Eur J Haematol. 2024 Jan 31. doi: 10.1111/ejh.14178.
     PubMed     Abstract available
     
     
     
132. PODGORICA M, Drivet E, Viken JK, Richman A, et al
     Transcriptome analysis of primary adult B-cell lineage acute lymphoblastic leukemia identifies pathogenic variants and gene fusions, and predicts subtypes for in depth molecular diagnosis.
     Eur J Haematol. 2024 Jan 8. doi: 10.1111/ejh.14164.
     PubMed     Abstract available
     
     
     
133. MOYEN TB, Tomaz V, Campregher PV
     Feasibility, accuracy, and usability analysis of MapAML, a first-in-class app for integrated diagnosis in acute myeloid leukemia.
     Eur J Haematol. 2024 Jan 3. doi: 10.1111/ejh.14158.
     PubMed     Abstract available
     
     
     
134. GUPTA S, Kohorst M, Alkhateeb HB
     Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
     Eur J Haematol. 2024;112:51-63.
     PubMed     Abstract available
     
     
     
135. WANG XY, Bian MR, Lin GQ, Yu L, et al
     Tandem bispecific CD123/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia.
     Eur J Haematol. 2024;112:83-93.
     PubMed     Abstract available
     
     
     
136. JI Q, Wu X, Zhang Y, Zeng L, et al
     Adverse events and efficacy of second-round CAR-T cell therapy in relapsed pediatric B-ALL.
     Eur J Haematol. 2024;112:75-82.
     PubMed     Abstract available
     
     
     
137. KHAN AN, Asija S, Pendhari J, Purwar R, et al
     CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
     Eur J Haematol. 2024;112:6-18.
     PubMed     Abstract available
     
     
     December 2023
138. TAMEFUSA K, Ochi M, Ishida H, Shiwaku T, et al
     Delayed diagnostic interval and survival outcomes in pediatric leukemia: A single-center, retrospective study.
     Eur J Haematol. 2023 Dec 28. doi: 10.1111/ejh.14162.
     PubMed     Abstract available
     
     
     
139. MORI T, Osumi T, Kada A, Ohki K, et al
     Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.
     Eur J Haematol. 2023 Dec 19. doi: 10.1111/ejh.14148.
     PubMed     Abstract available
     
     
     
140. NEUMANN MA, Nieper P, Simon F, Shimabukuro-Vornhagen A, et al
     A diagnostic challenge-First case of chronic lymphatic leukemia-associated necrotizing sweet syndrome.
     Eur J Haematol. 2023 Dec 17. doi: 10.1111/ejh.14153.
     PubMed     Abstract available
     
     
     
141. COSTA A, Carmosino I, Scalzulli E, Minotti C, et al
     Early death risk score in acute promyelocytic leukemia: A retrospective analysis from a monocentric cohort.
     Eur J Haematol. 2023 Dec 14. doi: 10.1111/ejh.14155.
     PubMed    
     
     
     
142. LAGANA A, Pepe S, Scalzulli E, Carmosino I, et al
     One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission.
     Eur J Haematol. 2023;111:970-972.
     PubMed    
     
     
     November 2023
143. NEVEJAN L, Labarque V, Boeckx N
     Chronic myeloid leukemia (CML) in children and adolescents-Clinicopathological findings.
     Eur J Haematol. 2023 Nov 20. doi: 10.1111/ejh.14137.
     PubMed     Abstract available
     
     
     
144. LEE BJ, Griffin SP, Doh J, Chan A, et al
     HyperCVAD versus pegaspargase-containing regimens for Hispanic adults with newly diagnosed B-cell acute lymphoblastic leukemia.
     Eur J Haematol. 2023 Nov 6. doi: 10.1111/ejh.14125.
     PubMed     Abstract available
     
     
     October 2023
145. SEGHATOL-ESLAMI VC, Cook EW 3rd, Sharafeldin N, Wolfson J, et al
     Adaptive functioning and academic achievement in pediatric survivors of acute lymphoblastic leukemia: Associations with executive functioning, socioeconomic status, and academic support.
     Eur J Haematol. 2023 Oct 5. doi: 10.1111/ejh.14112.
     PubMed     Abstract available
     
     
     
146. KRISTENSEN DT, Brondum RF, Orskov AD, Marcher CW, et al
     Venetoclax-based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy.
     Eur J Haematol. 2023;111:573-582.
     PubMed     Abstract available
     
     
     
147. MIYAJIMA T, Onozawa M, Yoshida S, Miyashita N, et al
     Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3-ITD positive AML.
     Eur J Haematol. 2023;111:620-627.
     PubMed     Abstract available
     
     
     
148. BREINHOLT MF, Schejbel L, Gang AO, Nielsen TH, et al
     Next generation sequencing in routine diagnostics of mature non-Hodgkin's B-cell lymphomas.
     Eur J Haematol. 2023;111:583-591.
     PubMed     Abstract available
     
     
     September 2023
149. AGRAWAL V, Murphy L, Pourhassan H, Pullarkat V, et al
     Optimizing CAR-T cell therapy in adults with B-cell acute lymphoblastic leukemia.
     Eur J Haematol. 2023 Sep 29. doi: 10.1111/ejh.14109.
     PubMed     Abstract available
     
     
     
150. KOCKEROLS C, Valk PJM, Blijlevens NMA, Cornelissen JJ, et al
     BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population.
     Eur J Haematol. 2023 Sep 20. doi: 10.1111/ejh.14107.
     PubMed     Abstract available
     
     
     
151. CHATTERJEE G, Dhende P, Raj S, Shetty V, et al
     15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges.
     Eur J Haematol. 2023 Sep 14. doi: 10.1111/ejh.14102.
     PubMed     Abstract available
     
     
     
152. ZARLING LC, Stevenson PA, Soma LA, Martino CH, et al
     Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia.
     Eur J Haematol. 2023 Sep 5. doi: 10.1111/ejh.14089.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum